에서 실시간으로 운영 중이에요! 자세히 알아보기

DaVita

DVA

시가총액 US$120억

187.31 USD

-1.85

0.98%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

187.31

0.00

0%

1일

-0.98%

5일

4.29%

1개월

-3.38%

3개월

-19.96%

6개월

26.45%

연초 이후

63.58%

1년

49.55%

5년

67.48%

10년

200.85%

소개: DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

직원 수: 78,000

건강관리 의료 시설

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 42.4%

중립 48.5%

부정적 9.1%

DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care

Seven studies spanning middle molecule clearance, home dialysis and patient experience highlight DaVita's commitment to translating innovation into better care DENVER, Oct. 15, 2026 /PRNewswire/ -- DaVita will present seven studies at the American Society of Nephrology (ASN) Kidney Week 2026, marking one of its most significant research presences at the conference in recent years. The research spans emerging approaches to middle molecule clearance, home dialysis and patient experience, underscoring DaVita's role in generating clinical evidence to help advance kidney care.

DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care

Zacks Investment Research

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today

In the latest trading session, DaVita HealthCare (DVA) closed at $179.25, marking a +1.26% move from the previous day.

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today

DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again

DaVita is rated Buy with a $220 12-month price target, offering 22% upside from current levels. Despite flat industry volumes and Medicare rate headwinds, DVA's aggressive buybacks drive most EPS growth, enhancing per-share value. At $180, DVA trades at 9.4x forward earnings, making buybacks more accretive and capital allocation more effective than at recent highs.

DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again

Zacks Investment Research

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DaVita gains from IKC growth, improving treatment economics and stronger formulary adoption, but payer-mix pressures and costs remain concerns.

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early

Patients encouraged to confirm treatment schedules, prepare emergency supplies and contact DaVita for assistance DENVER, Oct. 8, 2026 /PRNewswire/ -- As Hurricane Isaias approaches the Gulf Coast and southeastern United States, DaVita has activated its emergency response plan to help patients continue receiving life-sustaining dialysis care and to support communities preparing for severe weather. The storm is expected to bring heavy rainfall, flooding, storm surge and high winds across portions of the region.

DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early

The Motley Fool

3 Berkshire Hathaway Holdings to Buy While They Sit at Least 15% Below Their Highs

American Express is the last remaining credit card stock in Berkshire's portfolio. The New York Times Company is bucking the trend of the struggling newspaper industry.

3 Berkshire Hathaway Holdings to Buy While They Sit at Least 15% Below Their Highs

Zacks Investment Research

DaVita HealthCare (DVA) Laps the Stock Market: Here's Why

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $178.69, denoting a +1.33% move from the preceding trading day.

DaVita HealthCare (DVA) Laps the Stock Market: Here's Why

The Motley Fool

This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.

DaVita reported double-digit EPS growth in the second quarter. Berkshire Hathaway owns roughly 45% of DaVita stock.

This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.

Zacks Investment Research

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw DaVita HealthCare (DVA) settling at $174.67, representing a -4.62% change from its previous close.

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note

3 Surging Stocks That Don't Need the AI Boom to Keep Winning

With AI companies—and related chip stocks—driving much of the market's performance this year, it's understandable that some investors are hesitant to put all their trust in a burgeoning industry, no matter how much momentum it seems to have. Fortunately, a number of non-AI stocks have stood out for their strong performance throughout the first part of 2026.

3 Surging Stocks That Don't Need the AI Boom to Keep Winning

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.